Literature DB >> 15530161

Monitoring adverse drug reactions: scales, profiles, and checklists.

S Jordan1, J Knight, D Pointon.   

Abstract

BACKGROUND: Globally, adverse drug reactions (ADRs) make a substantial contribution to ill health. Introducing a systematic approach to patient surveillance could mitigate these problems. Formalized medication monitoring schedules have been proposed as one strategy to diagnose and action side-effects and the problems emanating from adverse drug reactions. To date, most developments have been linked to antipsychotic medications. Several scales, checklists, and side-effect profiles are available, including the West Wales ADR (adverse drug reaction) profile. However, relatively little work has been undertaken on the clinical validity, reliability, and sensitivity of these instruments. AIM: This paper describes the development of the monitoring schedule approach to medication management. It also reviews and compares the instruments available for monitoring the adverse drug reactions of antipsychotic medications. The UKU (Udvalg for Kliniske Undersogelser) scale and the West Wales ADR profile assess a broader range of physiological parameters and potential problems than other instruments. However, to be adopted in practice, such instruments must achieve a balance between clinical gain and practical cost, including the time spent in administration.
CONCLUSION: Further work is needed to explore the translation of formalized ADR surveillance programmes into clinical gains and improved outcomes for clients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530161     DOI: 10.1111/j.1466-7657.2004.00251.x

Source DB:  PubMed          Journal:  Int Nurs Rev        ISSN: 0020-8132            Impact factor:   2.871


  13 in total

1.  Resident and nurse reports of potential adverse drug reactions.

Authors:  Tinne Dilles; Bart Van Rompaey; Peter Van Bogaert; Monique M Elseviers
Journal:  Eur J Clin Pharmacol       Date:  2015-04-24       Impact factor: 2.953

2.  Neuropsychiatric sequelae in an efavirenz treated patient with hepatitis B.

Authors:  Emma Salter; Anish S Patel
Journal:  BMJ Case Rep       Date:  2009-11-26

3.  Effect of dose timing in relation to food intake on systemic exposure to blonanserin.

Authors:  Junji Saruwatari; Norio Yasui-Furukori; Yoshimasa Inoue; Sunao Kaneko
Journal:  Eur J Clin Pharmacol       Date:  2010-05-20       Impact factor: 2.953

4.  Nurse-Led Medicines' Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped Wedge Cluster Randomised Trial.

Authors:  Susan Jordan; Marie Ellenor Gabe-Walters; Alan Watkins; Ioan Humphreys; Louise Newson; Sherrill Snelgrove; Michael S Dennis
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

5.  A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders.

Authors:  Taro Kishi; Yuki Matsuda; Shinji Matsunaga; Tomohiko Mukai; Masatsugu Moriwaki; Hideaki Tabuse; Kiyoshi Fujita; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2016-11-28       Impact factor: 2.570

6.  Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial.

Authors:  Taro Kishi; Yuki Matsuda; Shinji Matsunaga; Masatsugu Moriwaki; Yoichiro Otake; Kaku Akamatsu; Tomo Okochi; Shigeki Hirano; Toshihiko Funahashi; Momoko Okuda; Hideaki Tabuse; Kiyoshi Fujita; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-06       Impact factor: 2.570

7.  Nurse-led medicines' monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines.

Authors:  Sue Jordan; Timothy Banner; Marie Gabe-Walters; Jane M Mikhail; Jeff Round; Sherrill Snelgrove; Mel Storey; Douglas Wilson; David Hughes
Journal:  BMJ Open       Date:  2018-09-28       Impact factor: 2.692

8.  Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles.

Authors:  Sue Jordan; Patricia A Logan; Gerwyn Panes; Mojtaba Vaismoradi; David Hughes
Journal:  Pharmacy (Basel)       Date:  2018-09-18

9.  Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring.

Authors:  Sue Jordan; Marie Gabe; Louise Newson; Sherrill Snelgrove; Gerwyn Panes; Aldo Picek; Ian T Russell; Michael Dennis
Journal:  ScientificWorldJournal       Date:  2014-02-23

10.  Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.

Authors:  Anjan K Banerjee; Sally Okun; I Ralph Edwards; Paul Wicks; Meredith Y Smith; Stephen J Mayall; Bruno Flamion; Charles Cleeland; Ethan Basch
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.